在雌性小鼠中,青春期促性腺激素水平的降低改变了生殖寿命和卵巢卵泡的损失。

IF 6 1区 医学 Q1 OBSTETRICS & GYNECOLOGY
Mélanie Chester, Marie M Devillers, Raphaël Corre, Frank Giton, Fatoumata Souaré, Claire-Hélène Petrovic, Éloïse Airaud, Daniel Quintas, Sakina Mhaouty-Kodja, Lydie Naulé, Céline J Guigon
{"title":"在雌性小鼠中,青春期促性腺激素水平的降低改变了生殖寿命和卵巢卵泡的损失。","authors":"Mélanie Chester, Marie M Devillers, Raphaël Corre, Frank Giton, Fatoumata Souaré, Claire-Hélène Petrovic, Éloïse Airaud, Daniel Quintas, Sakina Mhaouty-Kodja, Lydie Naulé, Céline J Guigon","doi":"10.1093/humrep/deaf019","DOIUrl":null,"url":null,"abstract":"<p><strong>Study question: </strong>What is the effect of attenuating the physiological hypergonadotropic activity encountered at minipuberty on female reproductive function in a mouse model?</p><p><strong>Summary answer: </strong>Decreasing the surge of gonadotropins at minipuberty extended reproductive lifespan, coinciding with alterations in neuroendocrine and ovarian aging.</p><p><strong>What is known already: </strong>Minipuberty is characterized by the tremendous activation of the gonadotrope axis, as evidenced by elevated levels of gonadotropins regulating folliculogenesis and the synthesis of ovarian hormones, but its role in fertility remains unclear.</p><p><strong>Study design, size, duration: </strong>To determine the link between gonadotrope axis activity at minipuberty and reproductive parameters, we used a pharmacological approach to suppress gonadotropin levels in Swiss mice by injecting daily a GnRH receptor antagonist (GnRHR) (Ganirelix, 10 µg/mouse) or its vehicle between 10 and 16 postnatal days, to cover the entire duration of minipuberty. We analyzed the onset of puberty and estrous cyclicity as well as fertility in young (3-5 months) and middle-aged (11 months) mice from control (CTR) and antagonist-treated groups (n = 17-20 mice/age and treatment group). Ovaries and brains were collected, fixed, and sectioned (for histology, follicle count, and immunohistochemistry) or frozen (for analysis of follicular markers, aging, and inflammation) from adult females, and blood was collected by cardiac puncture for hormonal assays (n = 3-8 mice/age and treatment group).</p><p><strong>Participants/materials, setting, methods: </strong>To analyze the initiation of puberty, we monitored vaginal opening and performed vaginal smears in CTR and antagonist-treated mice. We studied estrous cyclicity on vaginal smears at the beginning of reproductive life. Mice were mated several times with males to assess fertility rates, delay of conception, and litter size. To evaluate ovarian function, we counted follicles at different stages and corpora lutea, and we determined the relative intra-ovarian abundance of key follicular markers by real-time RT-PCR, as well as the levels of circulating anti-Müllerian hormone (AMH) and progesterone by ELISA and GC-MS, respectively. We also analyzed features of ovarian aging and inflammation by histology and by measuring the relative intra-ovarian abundance of some markers using real-time RT-PCR. To determine the impact on neuroendocrine determinants related to the CTR of reproduction, we analyzed circulating gonadotropin levels using Luminex assays as well as kisspeptin and GnRH immunoreactivity in the hypothalamus by immunohistochemistry.</p><p><strong>Main results and the role of chance: </strong>Our results show that the treatment had no impact on the initiation of puberty, estrous cyclicity, or fertility at the beginning of reproductive life. However, it increased reproductive lifespan, as shown by the higher percentage of antagonist-treated females than CTRs still fertile at 11 months of age (33% versus 6%; P = 0.0471). There were no significant differences in the number of kisspeptin and GnRH neurons, nor in the density of kisspeptin- and GnRH-immunoreactive neurons in the hypothalamic areas involved in reproduction between the two groups of mice studied at either 4 or 11 months. In addition, basal levels of FSH were comparable between the two groups at 4 and 11 months, but not those of LH at 11 months which were much lower in females treated with antagonist than in their age-matched CTRs (237 ± 59.6 pg/ml in antagonist-treated females versus 1027 ± 226.3 pg/ml in CTRs, P = 0.0069). Importantly, at this age, antagonist-treated mice had basal LH levels comparable to young mice (e.g. in 4-month-old CTRs: 294 ± 71.75 pg/ml, P > 0.05). Despite their prolonged reproductive lifespan and delayed neuroendocrine aging, antagonist-treated mice exhibited earlier depletion of their follicles, as shown by lower numbers of primordial, primary, and preantral follicles associated with lower circulating AMH levels and relative intra-ovarian abundance of Amh transcripts than CTR mice. However, they exhibited comparable completion of folliculogenesis, as suggested by the numbers of antral follicles and corpora lutea, relative intra-ovarian abundance of Cyp19a1, Inhba, and Inhbb transcripts, and circulating progesterone levels that all remained similar to those of the CTR group. These observed alterations in ovarian function were not associated with increased ovarian aging or inflammation.</p><p><strong>Large-scale data: </strong>None.</p><p><strong>Limitations, reasons for caution: </strong>This study was carried out on mice, which is a validated research model. However, human research is needed for further validation.</p><p><strong>Wider implications of the findings: </strong>This study, which is the first to investigate the physiological role of minipuberty on reproductive parameters, supports the idea that suppressing the high postnatal levels of gonadotropins may have long-term effects on female fertility by extending the duration of reproductive life. Perturbations in gonadotropin levels during this period of life, such as those observed in infants born prematurely, may thus have profound consequences on late reproductive functions.</p><p><strong>Study funding/competing interest(s): </strong>This research was conducted with the financial support of ANR AAPG2020 (ReproFUN), CNRS, Inserm, Université Paris Cité, and Sorbonne Université. The authors declare that they have no conflicts of interest.</p>","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":"717-729"},"PeriodicalIF":6.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965786/pdf/","citationCount":"0","resultStr":"{\"title\":\"Reduction in minipubertal gonadotropin levels alters reproductive lifespan and ovarian follicular loss in female mice.\",\"authors\":\"Mélanie Chester, Marie M Devillers, Raphaël Corre, Frank Giton, Fatoumata Souaré, Claire-Hélène Petrovic, Éloïse Airaud, Daniel Quintas, Sakina Mhaouty-Kodja, Lydie Naulé, Céline J Guigon\",\"doi\":\"10.1093/humrep/deaf019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Study question: </strong>What is the effect of attenuating the physiological hypergonadotropic activity encountered at minipuberty on female reproductive function in a mouse model?</p><p><strong>Summary answer: </strong>Decreasing the surge of gonadotropins at minipuberty extended reproductive lifespan, coinciding with alterations in neuroendocrine and ovarian aging.</p><p><strong>What is known already: </strong>Minipuberty is characterized by the tremendous activation of the gonadotrope axis, as evidenced by elevated levels of gonadotropins regulating folliculogenesis and the synthesis of ovarian hormones, but its role in fertility remains unclear.</p><p><strong>Study design, size, duration: </strong>To determine the link between gonadotrope axis activity at minipuberty and reproductive parameters, we used a pharmacological approach to suppress gonadotropin levels in Swiss mice by injecting daily a GnRH receptor antagonist (GnRHR) (Ganirelix, 10 µg/mouse) or its vehicle between 10 and 16 postnatal days, to cover the entire duration of minipuberty. We analyzed the onset of puberty and estrous cyclicity as well as fertility in young (3-5 months) and middle-aged (11 months) mice from control (CTR) and antagonist-treated groups (n = 17-20 mice/age and treatment group). Ovaries and brains were collected, fixed, and sectioned (for histology, follicle count, and immunohistochemistry) or frozen (for analysis of follicular markers, aging, and inflammation) from adult females, and blood was collected by cardiac puncture for hormonal assays (n = 3-8 mice/age and treatment group).</p><p><strong>Participants/materials, setting, methods: </strong>To analyze the initiation of puberty, we monitored vaginal opening and performed vaginal smears in CTR and antagonist-treated mice. We studied estrous cyclicity on vaginal smears at the beginning of reproductive life. Mice were mated several times with males to assess fertility rates, delay of conception, and litter size. To evaluate ovarian function, we counted follicles at different stages and corpora lutea, and we determined the relative intra-ovarian abundance of key follicular markers by real-time RT-PCR, as well as the levels of circulating anti-Müllerian hormone (AMH) and progesterone by ELISA and GC-MS, respectively. We also analyzed features of ovarian aging and inflammation by histology and by measuring the relative intra-ovarian abundance of some markers using real-time RT-PCR. To determine the impact on neuroendocrine determinants related to the CTR of reproduction, we analyzed circulating gonadotropin levels using Luminex assays as well as kisspeptin and GnRH immunoreactivity in the hypothalamus by immunohistochemistry.</p><p><strong>Main results and the role of chance: </strong>Our results show that the treatment had no impact on the initiation of puberty, estrous cyclicity, or fertility at the beginning of reproductive life. However, it increased reproductive lifespan, as shown by the higher percentage of antagonist-treated females than CTRs still fertile at 11 months of age (33% versus 6%; P = 0.0471). There were no significant differences in the number of kisspeptin and GnRH neurons, nor in the density of kisspeptin- and GnRH-immunoreactive neurons in the hypothalamic areas involved in reproduction between the two groups of mice studied at either 4 or 11 months. In addition, basal levels of FSH were comparable between the two groups at 4 and 11 months, but not those of LH at 11 months which were much lower in females treated with antagonist than in their age-matched CTRs (237 ± 59.6 pg/ml in antagonist-treated females versus 1027 ± 226.3 pg/ml in CTRs, P = 0.0069). Importantly, at this age, antagonist-treated mice had basal LH levels comparable to young mice (e.g. in 4-month-old CTRs: 294 ± 71.75 pg/ml, P > 0.05). Despite their prolonged reproductive lifespan and delayed neuroendocrine aging, antagonist-treated mice exhibited earlier depletion of their follicles, as shown by lower numbers of primordial, primary, and preantral follicles associated with lower circulating AMH levels and relative intra-ovarian abundance of Amh transcripts than CTR mice. However, they exhibited comparable completion of folliculogenesis, as suggested by the numbers of antral follicles and corpora lutea, relative intra-ovarian abundance of Cyp19a1, Inhba, and Inhbb transcripts, and circulating progesterone levels that all remained similar to those of the CTR group. These observed alterations in ovarian function were not associated with increased ovarian aging or inflammation.</p><p><strong>Large-scale data: </strong>None.</p><p><strong>Limitations, reasons for caution: </strong>This study was carried out on mice, which is a validated research model. However, human research is needed for further validation.</p><p><strong>Wider implications of the findings: </strong>This study, which is the first to investigate the physiological role of minipuberty on reproductive parameters, supports the idea that suppressing the high postnatal levels of gonadotropins may have long-term effects on female fertility by extending the duration of reproductive life. Perturbations in gonadotropin levels during this period of life, such as those observed in infants born prematurely, may thus have profound consequences on late reproductive functions.</p><p><strong>Study funding/competing interest(s): </strong>This research was conducted with the financial support of ANR AAPG2020 (ReproFUN), CNRS, Inserm, Université Paris Cité, and Sorbonne Université. The authors declare that they have no conflicts of interest.</p>\",\"PeriodicalId\":13003,\"journal\":{\"name\":\"Human reproduction\",\"volume\":\" \",\"pages\":\"717-729\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965786/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human reproduction\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/humrep/deaf019\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human reproduction","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/humrep/deaf019","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

研究问题:在小鼠模型中,减弱青春期前期生理高促性腺活性对雌性生殖功能的影响是什么?摘要回答:青春期前期减少促性腺激素的激增可以延长生殖寿命,同时神经内分泌和卵巢衰老也会发生改变。已知情况:青春期的特点是促性腺激素轴的大量激活,这可以通过促性腺激素水平升高来调节卵泡生成和卵巢激素的合成来证明,但它在生育中的作用尚不清楚。研究设计、大小、持续时间:为了确定青春期前期促性腺激素轴活性与生殖参数之间的联系,我们采用药理学方法,通过在出生后10至16天每天注射GnRH受体拮抗剂(GnRHR) (Ganirelix, 10µg/只)或其载体,抑制瑞士小鼠的促性腺激素水平,以覆盖整个青春期前期。我们分析了对照组(CTR)和拮抗剂治疗组(17-20只/年龄和治疗组)年轻(3-5个月)和中年(11个月)小鼠的青春期开始和发情周期以及生育能力。收集、固定、切片(用于组织学、卵泡计数和免疫组织化学)或冷冻(用于分析卵泡标记物、衰老和炎症)成年女性的卵巢和大脑,并通过心脏穿刺采集血液进行激素检测(n = 3-8只小鼠/年龄和治疗组)。参与者/材料,环境,方法:为了分析青春期的开始,我们在CTR和拮抗剂治疗的小鼠中监测阴道开口并进行阴道涂片。我们研究了生殖期开始时阴道涂片的发情周期。老鼠与雄性交配几次,以评估生育率、受孕延迟和产仔数。为了评估卵巢功能,我们统计了不同阶段的卵泡和黄体,并通过实时荧光定量pcr检测了卵巢内关键卵泡标志物的相对丰度,ELISA和GC-MS分别检测了循环抗<s:1>勒氏杆菌激素(AMH)和孕酮水平。我们还通过组织学分析了卵巢衰老和炎症的特征,并使用实时RT-PCR测量了卵巢内一些标志物的相对丰度。为了确定与生殖CTR相关的神经内分泌决定因素的影响,我们使用Luminex分析循环促性腺激素水平,并通过免疫组织化学分析下丘脑中的kisspeptin和GnRH免疫反应性。主要结果和偶然性的作用:我们的结果表明,治疗对青春期开始、发情周期或生殖生命开始时的生育能力没有影响。然而,它延长了生殖寿命,在11个月大时,拮抗剂治疗的雌性比对照组仍有生育能力的百分比更高(33%比6%;p = 0.0471)。在4个月或11个月时,两组小鼠在下丘脑区域参与生殖的kisspeptin和GnRH免疫反应神经元的数量和密度上没有显著差异。此外,两组在4个月和11个月时FSH的基础水平具有可比性,但11个月时LH的基础水平不具有可比性,在接受拮抗剂治疗的女性中,LH的基础水平远低于同龄对照组(拮抗剂治疗的女性为237±59.6 pg/ml,而对照组为1027±226.3 pg/ml, P = 0.0069)。重要的是,在这个年龄,拮抗剂治疗小鼠的基础LH水平与年轻小鼠相当(例如,在4个月大的CTRs中:294±71.75 pg/ml, P < 0.05)。尽管它们的生殖寿命延长,神经内分泌老化延迟,拮抗剂处理的小鼠表现出更早的卵泡损耗,这表明与CTR小鼠相比,原始卵泡、初级卵泡和前卵泡的数量更少,循环AMH水平更低,卵巢内AMH转录物的相对丰度也更低。然而,他们表现出相当的卵泡形成完成,如窦卵泡和黄体的数量,卵巢内Cyp19a1、Inhba和Inhbb转录本的相对丰度,以及循环孕酮水平,这些都与CTR组相似。这些观察到的卵巢功能改变与卵巢老化或炎症增加无关。大规模数据:无。局限性,谨慎的原因:本研究是在小鼠身上进行的,这是一个经过验证的研究模型。然而,需要人体研究来进一步验证。研究结果的更广泛意义:这项研究首次调查了青春期过短对生殖参数的生理作用,支持了这样一种观点,即抑制出生后高水平的促性腺激素可能通过延长生殖寿命对女性生育能力产生长期影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Reduction in minipubertal gonadotropin levels alters reproductive lifespan and ovarian follicular loss in female mice.

Study question: What is the effect of attenuating the physiological hypergonadotropic activity encountered at minipuberty on female reproductive function in a mouse model?

Summary answer: Decreasing the surge of gonadotropins at minipuberty extended reproductive lifespan, coinciding with alterations in neuroendocrine and ovarian aging.

What is known already: Minipuberty is characterized by the tremendous activation of the gonadotrope axis, as evidenced by elevated levels of gonadotropins regulating folliculogenesis and the synthesis of ovarian hormones, but its role in fertility remains unclear.

Study design, size, duration: To determine the link between gonadotrope axis activity at minipuberty and reproductive parameters, we used a pharmacological approach to suppress gonadotropin levels in Swiss mice by injecting daily a GnRH receptor antagonist (GnRHR) (Ganirelix, 10 µg/mouse) or its vehicle between 10 and 16 postnatal days, to cover the entire duration of minipuberty. We analyzed the onset of puberty and estrous cyclicity as well as fertility in young (3-5 months) and middle-aged (11 months) mice from control (CTR) and antagonist-treated groups (n = 17-20 mice/age and treatment group). Ovaries and brains were collected, fixed, and sectioned (for histology, follicle count, and immunohistochemistry) or frozen (for analysis of follicular markers, aging, and inflammation) from adult females, and blood was collected by cardiac puncture for hormonal assays (n = 3-8 mice/age and treatment group).

Participants/materials, setting, methods: To analyze the initiation of puberty, we monitored vaginal opening and performed vaginal smears in CTR and antagonist-treated mice. We studied estrous cyclicity on vaginal smears at the beginning of reproductive life. Mice were mated several times with males to assess fertility rates, delay of conception, and litter size. To evaluate ovarian function, we counted follicles at different stages and corpora lutea, and we determined the relative intra-ovarian abundance of key follicular markers by real-time RT-PCR, as well as the levels of circulating anti-Müllerian hormone (AMH) and progesterone by ELISA and GC-MS, respectively. We also analyzed features of ovarian aging and inflammation by histology and by measuring the relative intra-ovarian abundance of some markers using real-time RT-PCR. To determine the impact on neuroendocrine determinants related to the CTR of reproduction, we analyzed circulating gonadotropin levels using Luminex assays as well as kisspeptin and GnRH immunoreactivity in the hypothalamus by immunohistochemistry.

Main results and the role of chance: Our results show that the treatment had no impact on the initiation of puberty, estrous cyclicity, or fertility at the beginning of reproductive life. However, it increased reproductive lifespan, as shown by the higher percentage of antagonist-treated females than CTRs still fertile at 11 months of age (33% versus 6%; P = 0.0471). There were no significant differences in the number of kisspeptin and GnRH neurons, nor in the density of kisspeptin- and GnRH-immunoreactive neurons in the hypothalamic areas involved in reproduction between the two groups of mice studied at either 4 or 11 months. In addition, basal levels of FSH were comparable between the two groups at 4 and 11 months, but not those of LH at 11 months which were much lower in females treated with antagonist than in their age-matched CTRs (237 ± 59.6 pg/ml in antagonist-treated females versus 1027 ± 226.3 pg/ml in CTRs, P = 0.0069). Importantly, at this age, antagonist-treated mice had basal LH levels comparable to young mice (e.g. in 4-month-old CTRs: 294 ± 71.75 pg/ml, P > 0.05). Despite their prolonged reproductive lifespan and delayed neuroendocrine aging, antagonist-treated mice exhibited earlier depletion of their follicles, as shown by lower numbers of primordial, primary, and preantral follicles associated with lower circulating AMH levels and relative intra-ovarian abundance of Amh transcripts than CTR mice. However, they exhibited comparable completion of folliculogenesis, as suggested by the numbers of antral follicles and corpora lutea, relative intra-ovarian abundance of Cyp19a1, Inhba, and Inhbb transcripts, and circulating progesterone levels that all remained similar to those of the CTR group. These observed alterations in ovarian function were not associated with increased ovarian aging or inflammation.

Large-scale data: None.

Limitations, reasons for caution: This study was carried out on mice, which is a validated research model. However, human research is needed for further validation.

Wider implications of the findings: This study, which is the first to investigate the physiological role of minipuberty on reproductive parameters, supports the idea that suppressing the high postnatal levels of gonadotropins may have long-term effects on female fertility by extending the duration of reproductive life. Perturbations in gonadotropin levels during this period of life, such as those observed in infants born prematurely, may thus have profound consequences on late reproductive functions.

Study funding/competing interest(s): This research was conducted with the financial support of ANR AAPG2020 (ReproFUN), CNRS, Inserm, Université Paris Cité, and Sorbonne Université. The authors declare that they have no conflicts of interest.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Human reproduction
Human reproduction 医学-妇产科学
CiteScore
10.90
自引率
6.60%
发文量
1369
审稿时长
1 months
期刊介绍: Human Reproduction features full-length, peer-reviewed papers reporting original research, concise clinical case reports, as well as opinions and debates on topical issues. Papers published cover the clinical science and medical aspects of reproductive physiology, pathology and endocrinology; including andrology, gonad function, gametogenesis, fertilization, embryo development, implantation, early pregnancy, genetics, genetic diagnosis, oncology, infectious disease, surgery, contraception, infertility treatment, psychology, ethics and social issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信